Pramlintide,the synthetic analogue of amylin: Physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk

Vascular Health and Risk Management

Volumn 4, Issue 2, 2008, Pages 355-362

  Hoogwerf, Byron J ^a,b   Doshi, Krupa B ^a   Diab, Dima ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

Diabetes mellitus; Glycemic control; Pramlintide

Indexed keywords

3 NITROTYROSINE; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN; BIOLOGICAL MARKER; CHOLESTEROL; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; PRAMLINTIDE; RECOMBINANT LEPTIN; SULFONYLUREA; SYNTHETIC PEPTIDE; TRIACYLGLYCEROL;

ADJUVANT THERAPY; ANOREXIA; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIET THERAPY; DOSAGE SCHEDULE COMPARISON; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; MICROANGIOPATHY; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; SATIETY; SIDE EFFECT; STOMACH EMPTYING; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CONTROL; WEIGHT GAIN; WEIGHT REDUCTION;

AMYLOID; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; OXIDATIVE STRESS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 44049097336     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Amiel SA, Heller SR, Macdonald IA, et al. 2005. The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes. Diabetes Obes Metab, 7:504-16.
2. Baron AD, Kim D, Weyer C 2002. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus. Curr Drug Targets Immune Endocr Metabol Disord, 2:63-82.
3. Blonde L, Klein EJ, Han J, et al. 2006. Interim analysis of the effects of exenatide treatment on AlC, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab, 8:436-47.
4. Ceriello A, Kumar S, Piconi L, et al. 2007. Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes. Diabetes Care, 30:649-54.
5. Ceriello A, Piconi L, Quagliaro L, et al. 2005. Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. Diabetes Care, 28:632-7.
6. Chapman I, Parker B, Doran S, et al. 2005. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia, 48:838-48.
7. DCCT Research Group. 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med, 329:977-86.
8. DCCT Research Group. 2001. Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care, 24:1711-21.
9. DCCT/EDIC Research Group. 2000. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med, 342:381-9.
10. Edelman S, Garg S, Frias J, et al. 2006. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care, 29:2189-95.
11. Fineman M, Bahner A, Gottlieb A, et al. 1999a. Effects of six months of administration of pramlintide as an adjunct to insulin therapy on metabolic control in people wtih type 1 diabetes. Diabetes, 48 (Suppl 1):A113.
12. Fineman M, Gottlieb A, Bahner A, et al. 1999b. Pramlintide therapy in addition to insulin in type 1 diabetes: effect on metabolic control after 6 months. Diabetologia, 42:A232 (abstract 0872).
13. Fineman M, Weyer C, Maggs DG, et al. 2002a. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res, 34:504-8.
14. Fineman MS, Koda JE, Shen LZ, et al. 2002b. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism, 51:636-41.
15. Gedulin BR, Rink TJ, Young AA. 1997. Dose-response for glucagonostatic effect of amylin in rats. Metabolism, 46:67-70.
16. Ghiselli A, Serafini M, Maiani G, et al. 1995. A fluorescence-based method for measuring total plasma antioxidant capability. Free Radic Biol Med, 18:29-36.
17. Giugliano D, Ceriello A, Paolisso G. 1996. Oxidative stress and diabetic vascular complications. Diabetes Care, 19:257-67.
18. Gottlieb A, Velte M, Fineman M, et al. 2000. Pramlintide as an adjunct to insuln therapy improved glycemic and weight control in people with type1 diabetes during treatment for 52 weeks. Diabetes, 49(Suppl 1):A109.
19. Gottlieb A, Fineman M, Bahner A. 2007. Pramlintide therapy in addition to insulin in type 2 diabetes: effect on metabolic control after 6 months. Diabetologia, 42(Suppl):A232.
20. Halford JC. 2006. Obesity drugs in clinical development. Curr Opin Investig Drugs, 7:312-18.
21. Hazen SL. 2000. Oxidation and atherosclerosis. Free Radic Biol Med, 28:1683-4.
22. Heptulla RA, Rodriguez LM, Bomgaars L, et al. 2005. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. Diabetes, 54:1100-7.
23. Hollander P, Maggs DG, Ruggles JA, et al. 2004. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res, 12:661-8.
24. Hollander P, Ratner R, Fineman M, et al. 2003a. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obes Metab, 5:408-14.
25. Hollander PA, Levy P, Fineman MS, et al. 2003b. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care, 26:784-90.
26. Hoogwerf BJ. 2006. Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus. Cleve Clin J Med, 73:477-84.
27. Hussar DA. 2005. New drugs: exenatide, pramlintide acetate, and micafungin sodium. J Am Pharm Assoc (2003), 45:524-7.
28. Kailasam MT, Parmer RJ, Tyrell EA, et al. 2000. Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk. J Hypertens, 18:1611-20.
29. Kleppinger EL, Vivian EM. 2003. Pramlintide for the treatment of diabetes mellitus. Ann Pharmacother, 37:1082-9.
30. Kolterman OG, Gottlieb A, Moyses C, et al. 1995. Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue. Diabetes Care, 18:1179-82.
31. Kolterman OG, Schwartz S, Corder C, et al. 1996. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia, 39:492-9.
32. Kong MF, Stubbs TA, King P, et al. 1998. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia, 41:577-83.
33. Levetan C, Want LL, Weyer C, et al. 2003. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care, 26:1-8.
34. Lutz TA, Del PE, Scharrer E. 1995. Subdiaphragmatic vagotomy does not influence the anorectic effect of amylin. Peptides, 16:457-62.
35. Marrero DG, Crean J, Zhang B, et al. 2007. Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care, 30:210-16.
36. Nicholls SJ, Hazen SL. 2004. The role of myeloperoxidase in the pathogenesis of coronary artery disease. Jpn J Infect Dis, 57:S21-S22.
37. Nicholls SJ, Hazen SL. 2005. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol, 25:1102-11.
38. Nogid A, Pham DQ. 2006. Adjunctive therapy with pramlintide in patients with type 1 or type 2 diabetes mellitus. Pharmacotherapy, 26:1626-40.
39. Nyholm B, Orskov L, Hove KY, et al. 1999. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patien ts with type 1 diabetes mellitus. Metabolism, 48:935-41.
40. Purnell JQ, Weyer C. 2003. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol, 2:33-47.
41. Ratner R, Whitehouse F, Fineman MS, et al. 2005. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. Exp Clin Endocrinol Diabetes, 113:199-204.
42. Ratner RE, Dickey R, Fineman M, et al. 2004. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med, 21:1204-12.
43. Ratner RE, Want LL, Fineman MS, et al. 2002. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther, 4:51-61.
44. Roth JD, Hughes H, Kendall E, et al. 2006. Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology, 147:5855-64.
45. Ryan GJ, Jobe LJ, Martin R. 2005. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther, 27:1500-12.
46. Schmitz O, Brock B, Rungby J. 2004. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes, 53(Suppl 3):S233-S8.
47. Shah P, Vella A, Basu A, et al. 2000. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab, 85:4053-9.
48. Shishehbor MH, Aviles RJ, Brennan ML, et al. 2003. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA, 289:1675-80.
49. Thompson RG, Pearson L, Kolterman OG. 1997a. Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations. Diabetologia, 40:1278-85.
50. Thompson RG, Pearson L, Schoenfeld SL, et al. 1998. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group. Diabetes Care, 21:987-93.
51. Thompson RG, Peterson J, Gottlieb A, et a;. 1997b. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes, 46:632-6.
52. UKPDS Research Group 1998a. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352:854-65.
53. UKPDS Study Group 1998b. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352:837-53.
54. Uwaifo GI, Ratner RE. 2005. Novel pharmacologic agents for type 2 diabetes. Endocrinol Metab Clin North Am, 34:155-97.
55. Vella A, Lee JS, Camilleri M, et al. 2002. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterol Motil, 14:123-31.
56. Want L. 2006. Use of pramlintide: the patient's perspective. Diabetes Educ, 32(Suppl 3):111S-18S.
57. Want LL, Ratner RE. 2006. Pramlintide: A new tool in diabetes management. Curr Diab Rep, 6:344-9.
58. Weyer C, Fineman MS, Strobel S, et al. 2005. Properties of pramlintide and insulin upon mixing. Am J Health Syst Pharm, 62:816-22.
59. Weyer C, Gottlieb A, Kim DD, et al. 2003. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care, 26:3074-9.
60. Weyer C, Maggs DG, Young AA, et al. G. 2001. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes metlitus: a physiological approach toward improved metabolic control. Curr Pharm Des, 7:1353-73.
61. Whitehouse F, Kruger DF, Fineman M, et al. 2002. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care, 25:724-30.
62. Young A. 2005. Tissue expression and secretion of amylin. Adv Pharmacol, 52:19-45.
63. Young A, Kolterman O, Hall J. 1999. Amylin innocent in essential hypertension? Diabetologia, 42:1029.